Rep. Gilbert Ray Cisneros, Jr. Buys Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ligand Pharmaceuticals stock on May 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Sold $15,001 – $50,000 in shares of Workday (NASDAQ:WDAY) on 5/29/2026.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock traded up $4.96 during trading on Wednesday, reaching $248.24. 240,039 shares of the company’s stock traded hands, compared to its average volume of 220,929. The firm’s 50-day moving average is $222.27 and its 200 day moving average is $205.66. The company has a market capitalization of $4.97 billion, a P/E ratio of 33.68, a PEG ratio of 2.53 and a beta of 1.17. Ligand Pharmaceuticals Incorporated has a 1 year low of $110.00 and a 1 year high of $257.19. The company has a current ratio of 21.28, a quick ratio of 20.95 and a debt-to-equity ratio of 0.45.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $1.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.84 by ($0.21). Ligand Pharmaceuticals had a net margin of 55.95% and a return on equity of 16.19%. The business had revenue of $51.72 million for the quarter, compared to the consensus estimate of $59.10 million. During the same period in the previous year, the firm earned $1.33 EPS. The company’s revenue was up 14.1% compared to the same quarter last year. Equities research analysts expect that Ligand Pharmaceuticals Incorporated will post 4.47 EPS for the current year.

Insider Buying and Selling

In other news, insider Andrew Reardon sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $227.06, for a total transaction of $1,135,300.00. Following the sale, the insider owned 41,382 shares of the company’s stock, valued at approximately $9,396,196.92. The trade was a 10.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Kozarich sold 1,575 shares of the stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $223.50, for a total value of $352,012.50. Following the completion of the transaction, the director directly owned 41,786 shares of the company’s stock, valued at $9,339,171. This represents a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 18,968 shares of company stock valued at $4,163,441 over the last three months. 7.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

LGND has been the topic of a number of recent research reports. HC Wainwright increased their price objective on Ligand Pharmaceuticals from $243.00 to $289.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Bank of America initiated coverage on shares of Ligand Pharmaceuticals in a report on Wednesday, March 11th. They issued a “buy” rating and a $244.00 price target on the stock. Oppenheimer lifted their price objective on Ligand Pharmaceuticals from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Friday, February 27th. Royal Bank Of Canada boosted their target price on Ligand Pharmaceuticals from $252.00 to $262.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Finally, Wall Street Zen cut Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Segall Bryant & Hamill LLC bought a new stake in Ligand Pharmaceuticals in the first quarter worth $1,337,000. Argent Capital Management LLC bought a new position in Ligand Pharmaceuticals during the 1st quarter worth approximately $696,000. Cim Investment Management Inc. increased its stake in Ligand Pharmaceuticals by 3.4% in the 1st quarter. Cim Investment Management Inc. now owns 1,484 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 49 shares during the period. Bank of America Corp DE lifted its position in Ligand Pharmaceuticals by 31.4% in the first quarter. Bank of America Corp DE now owns 157,865 shares of the biotechnology company’s stock valued at $31,518,000 after purchasing an additional 37,696 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Ligand Pharmaceuticals by 1.5% during the first quarter. Janus Henderson Group PLC now owns 1,009,891 shares of the biotechnology company’s stock valued at $201,623,000 after purchasing an additional 14,491 shares during the period. 91.28% of the stock is currently owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.